Short answer
IRADIMED CORP (IRMD) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $21M (up 15.7% year over year) with net income of $6M.
Q3 2025 key financials · XBRL
- Revenue
- $21M
- +15.7% YoY · +3.9% QoQ
- Net income
- $6M
- +10.4% YoY · −3.4% QoQ
- Operating margin
- 32.2%
- Gross margin
- 77.8%
- EPS (diluted)
- $0.43
- +10.3% YoY · −4.4% QoQ
Source: XBRL data from the IRADIMED CORP (IRMD) Q3 2025 10-Q on SEC EDGAR. USD.
IRADIMED CORP Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $21.2M for Q3 2025, up 16% YoY from $18.3M in Q3 2024; nine months revenue $61.1M, up 13% from $53.9M
- Gross margin 78% Q3 2025 vs 77% Q3 2024; nine months margin steady at 77% both years
- Best segment Devices revenue up 20% to $15.6M Q3 2025; worst Services revenue down 16% to $0.9M Q3 2025
- Cash and equivalents increased to $56.5M Sep 30, 2025 from $52.2M Dec 31, 2024; operating cash flow $19.0M YTD vs $19.6M prior year
- Management expects sufficient liquidity for next 12 months; no new capital planned but may seek debt or equity if needed
Risk Factors
- No newly added risk factors disclosed this quarter; section continues prior risks without material updates
- Most materially updated risk: increased regulatory expenses driven by expanded FDA requirements and ongoing post-market surveillance programs
- Regulatory risk: compliance with FDA medical device regulations amid intensified scrutiny of MRI-compatible technologies and adherence to quality system requirements
- Operational risk: extended sales cycles of 3-6 months and dependence on GPO agreements with 3% fees impacting U.S. hospital sales execution
- Financial risk: revenue growth 16% YoY to $21.2M this quarter with rising operating expenses including marketing and regulatory costs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IRADIMED CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.